Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK NICE To Pharma Firms: Up Your Game In Horizon Scanning

Executive Summary

Pharmaceutical companies must play a fuller part in planning for health technology appraisals by NICE, which has resource limitations and cannot do everything that companies might expect of it, a recent workshop in London heard.

You may also be interested in...



UK’s NICE Price Discounts ‘Pass Risk To Patients’

Health technology appraisal mechanisms like discounts do nothing to address a lack of clinical evidence and simply transfer the uncertainty to patients, NICE’s recent annual conference heard.

ABPI Exec Lauds Innovation And Access Provisions In New UK Voluntary Scheme

Speakers at a meeting in London examined the key provisions of the new voluntary pricing and access scheme, which replaced the PPRS at the beginning of January. The Pink Sheet spoke to the Association of the British Pharmaceutical Industry’s Paul Catchpole about enhanced planning for the introduction of new treatments on the national health service, and the shape of the new “commercial flexibilities” intended to allow earlier patient access to innovation.

UK NICE Review Will Look At Criteria For Appraising Highly Specialized Products

The UK's HTA body, NICE, says a more scientific criteria should be used to decide how many products should be admitted to its program for evaluating highly specialized technologies.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS125238

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel